|
|
|
News For AZN;MYL;TEVA From The Last 14 Days Check below for free stories on AZN;MYL;TEVA the last two weeks. |
|
|
| June 12, 2013 | | 08:23 EDT |  | TEVA | Teva, Active Biotech announces results of Phase IIa study of laquinimod
 Subscribe for More Information | | | 08:09 EDT | | TEVA | Teva's Laquinimod for lupus reports positive Phase II results
Subscribe for More Information | | | 08:02 EDT | | TEVA | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information | | | 07:08 EDT |  | TEVA | Drugstores ready access changes to Plan B pill, WSJ reports
Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, reports the Wall Street Journal.Reference Link | | | 06:05 EDT | | TEVA | On the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: The tectonic plates of the world economy are shifting, moving the yield on the 10-year Treasury to the highest level in more than a year and shaking financial markets. Now, some constants are being questioned in markets, triggering paroxysms in stocks, bonds, commodities and the currencies of emerging markets, the Wall Street Journal reports...Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, the Wall Street Journal reports...REUTERS: If currency turbulence in emerging markets becomes a full-scale investor flight, the Fed may have a new headache in deciding when to slow its dollar printing policy. The link between U.S. monetary policy and currency runs on the other side of the world could be tighter than many assume, Reuters reports...Toyota Motor (TM) said it’s unlikely to recapture its peak market share it held four years ago in the U.S. (GM, F), its biggest market, the latest sign the carmaker is shifting to improving quality from aggressively expanding sales, Reuters reports...BLOOMBERG: Exchange executives (NYX, NDAQ), long shielded from legal scrutiny in the U.S., have been put on notice that may be changing after federal regulators fined CBOE Holdings (CBOE) $6M for unprecedented lapses in supervision, Bloomberg reports...Borealis Infrastructure Management and its Kuwaiti-British partners abandoned their $8.3B bid for the U.K. water utility Severn Trent (SVTRY) as the offer deadline expired, Bloomberg reports. | | | June 11, 2013 | | 10:56 EDT | | AZN | AstraZeneca to bid for Israeli biotech incubator, Globes reports
Subscribe for More Information | | | 05:50 EDT | | TEVA | U.S. to now comply with ruling on morning-after pill, WSJ reports
In a reversal, the U.S. government said it would allow emergency contraceptive Plan B to be sold in drugstores without restrictions and would end an appeal in a long-running court case, reports the Wall Street Journal. Reference Link | | | June 10, 2013 | | 07:20 EDT |  | TEVA | Biomed to host a conference
Subscribe for More Information | | | 05:25 EDT | | AZN | AstraZeneca acquires Pearl Therapeutics for up to $1.15B
AstraZeneca announced that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Under the terms of the agreement, AstraZeneca will acquire 100% of Pearl's shares for initial consideration of $560M payable on completion. In addition, deferred consideration of up to $450M becomes payable if specified development and regulatory milestones in respect of any triple combination therapies and selected future products that AstraZeneca develops using Pearl's technology platform are achieved. Sales-related payments of up to a further $140M are payable if pre-agreed cumulative sales thresholds are exceeded resulting in a total potential acquisition cost of up to $1.15B. The proposed transaction is subject to customary regulatory approvals and is expected to close in the Q3 of 2013. The acquisition of Pearl Therapeutics has no impact on AstraZeneca's financial guidance for 2013. | | | June 6, 2013 | | 08:30 EDT | | TEVA | Federal appeals court orders access to contraceptive, WSJ reports
Subscribe for More Information | | | | 07:33 EDT |  | TEVA | Teva Laquinimod could become $1B franchise, says Bernstein
Subscribe for More Information | | | 07:01 EDT | | AZN | Isis Pharmaceuticals earns $6M payment from AstraZeneca
Subscribe for More Information | |
|
|
|
|
|
|
